-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Establishment Labs (NASDAQ:ESTA) Stock Price Up 7.8%
Establishment Labs (NASDAQ:ESTA) Stock Price Up 7.8%
Establishment Labs Holdings Inc. (NASDAQ:ESTA – Get Rating) rose 7.8% during mid-day trading on Thursday . The company traded as high as $69.60 and last traded at $69.39. Approximately 3,896 shares changed hands during mid-day trading, a decline of 96% from the average daily volume of 110,256 shares. The stock had previously closed at $64.37.
Analysts Set New Price Targets
ESTA has been the topic of a number of recent analyst reports. Stephens dropped their price target on shares of Establishment Labs from $90.00 to $87.00 and set an "overweight" rating on the stock in a research report on Wednesday, December 28th. Mizuho assumed coverage on shares of Establishment Labs in a research report on Wednesday, October 12th. They set a "buy" rating and a $70.00 target price on the stock. Finally, BTIG Research boosted their target price on shares of Establishment Labs from $90.00 to $100.00 and gave the company a "buy" rating in a research report on Friday, October 7th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, Establishment Labs presently has an average rating of "Moderate Buy" and an average target price of $97.00.
Get Establishment Labs alerts:Establishment Labs Price Performance
The stock's 50 day simple moving average is $63.87 and its 200 day simple moving average is $60.34. The company has a debt-to-equity ratio of 97.56, a quick ratio of 3.29 and a current ratio of 4.27.
Establishment Labs (NASDAQ:ESTA – Get Rating) last announced its quarterly earnings results on Monday, November 7th. The company reported ($0.76) EPS for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.27). The business had revenue of $38.25 million for the quarter, compared to the consensus estimate of $37.55 million. Establishment Labs had a negative net margin of 49.50% and a negative return on equity of 209.77%. During the same quarter last year, the firm posted ($0.61) EPS. Analysts forecast that Establishment Labs Holdings Inc. will post -2.6 EPS for the current year.Institutional Trading of Establishment Labs
Hedge funds and other institutional investors have recently bought and sold shares of the business. BNP Paribas Arbitrage SA grew its stake in shares of Establishment Labs by 3,244.4% in the 1st quarter. BNP Paribas Arbitrage SA now owns 602 shares of the company's stock worth $41,000 after acquiring an additional 584 shares in the last quarter. Lazard Asset Management LLC grew its stake in shares of Establishment Labs by 104.5% in the 1st quarter. Lazard Asset Management LLC now owns 963 shares of the company's stock worth $64,000 after acquiring an additional 492 shares in the last quarter. BNP Paribas Arbitrage SNC grew its stake in shares of Establishment Labs by 100.6% in the 3rd quarter. BNP Paribas Arbitrage SNC now owns 1,689 shares of the company's stock worth $92,000 after acquiring an additional 847 shares in the last quarter. Bank of America Corp DE grew its stake in shares of Establishment Labs by 38.4% in the 1st quarter. Bank of America Corp DE now owns 2,227 shares of the company's stock worth $150,000 after acquiring an additional 618 shares in the last quarter. Finally, Twin Lakes Capital Management LLC bought a new stake in shares of Establishment Labs in the 3rd quarter worth $163,000. Institutional investors own 75.26% of the company's stock.
About Establishment Labs
(Get Rating)
Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander, as well as distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution.
See Also
- Get a free copy of the StockNews.com research report on Establishment Labs (ESTA)
- MarketBeat: Week in Review 01/09-01/13
- JPMorgan Chase Falls As Banks Brace For Recession
- Why is the Bed Bath & Beyond Stock Price up 261%?
- Roku Stock Price is Trending, Here's Why
- Carvana Stock Rally, Here's What You Need to Know
Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.
成立實驗室控股公司(納斯達克代碼：ESTA-GET評級)週四午盤上漲7.8%。該公司股價一度高達69.60美元，最新報69.39美元。午盤交易中，約有3,896股易手，較110,256股的日均成交量下降了96%。該股此前收盤價為64.37美元。
分析師設定新的價格目標
ESTA一直是最近許多分析師報告的主題。斯蒂芬斯在12月28日(星期三)的一份研究報告中將機構實驗室的股票目標價從90.00美元下調至87.00美元，並對該股設定了“增持”評級。瑞穗在10月12日星期三的一份研究報告中對建立實驗室的股票進行了報道。他們為該股設定了“買入”評級和70.00美元的目標價。最後，BTIG Research將其股票目標價從90美元上調至100.00美元，並在10月7日星期五的一份研究報告中給予該公司“買入”評級。一名投資分析師對該股的評級為持有，四名分析師對該股的評級為買入。根據MarketBeat.com的數據，機構實驗室目前的平均評級為“中等買入”，平均目標價為97.00美元。
到達建立實驗室警報：設施實驗室性價比
該股的50日簡單移動均線切入位為63.87美元，200日簡單移動均線切入位為60.34美元。該公司的負債權益比率為97.56，速動比率為3.29，流動比率為4.27。
成立實驗室(納斯達克代碼：ESTA-GET Rating)上一次公佈季度收益是在11月7日星期一。該公司公佈本季度每股收益(0.76美元)，低於分析師普遍預期的(0.49美元)至(0.27美元)。該業務本季度的收入為3825萬美元，而普遍預期為3755萬美元。成立實驗室的淨利潤率為負49.50%，淨資產回報率為負209.77%。去年同期，該公司公佈的每股收益為0.61美元。分析師預測，機構實驗室控股公司本年度每股收益將達到2.6歐元。機構實驗室的制度性交易
對沖基金和其他機構投資者最近買賣了該公司的股票。第一季度，法國巴黎銀行套利公司在機構實驗室的持股增加了3,244.4%。法國巴黎銀行套利公司現在持有602股該公司股票，價值41,000美元，上個季度又購入了584股。Lazard Asset Management LLC在第一季度持有的機構實驗室股份增加了104.5%。Lazard Asset Management LLC在上個季度增持了492股後，現在擁有963股該公司股票，價值6.4萬美元。法國巴黎銀行套利SNC在第三季度持有的機構實驗室股份增加了100.6%。法國巴黎銀行套利SNC現在擁有1,689股該公司股票，價值92,000美元，上個季度又收購了847股。今年第一季度，美國銀行(Bank Of America Corp DE)在機構實驗室的持股增加了38.4%。美國銀行DE目前持有2,227股該公司股票，價值15萬美元，此前該公司在上個季度增持了618股。最後，雙湖資本管理有限責任公司在第三季度購買了價值16.3萬美元的建立實驗室新股。機構投資者持有該公司75.26%的股份。
關於機構實驗室
(獲取評級)
建立實驗室控股公司是一家醫療技術公司，生產和營銷用於美容和重建整形手術的醫療器械。該公司主要提供Motiva Implants品牌下的矽膠填充乳房植入物。它還提供Motiva Ergonomix和Motiva Ergonomix2重力敏感圓形軟矽膠填充型乳房植入物；以及Motiva Flora組織擴張器，以及分銷用於自體脂肪組織採集和再分配的純移植物系列產品。
另請參閱
- 免費獲取StockNews.com關於機構實驗室的研究報告(ESTA)
- MarketBeat：回顧中的一週01/09-01/13
- 摩根大通破產，銀行為衰退做好準備
- 為什麼Bed Bath&Beyond的股價上漲了261%？
- Roku股價走勢，原因如下
- Carvana Stock Rally，這是你需要知道的
接受機構實驗室每日的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對機構實驗室和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧